$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000162828015006531 Filed on August 12, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$11.31M	$13.59M	$4.432M
YoY Change	17.09%	206.63%	147633.33%
Cost Of Revenue	$6.772M	$6.901M	$5.009M
YoY Change	22.42%	37.77%	500800.0%
Gross Profit	$4.537M	$6.689M	-$577.0K
YoY Change	9.96%	-1259.27%	-28950.0%
Gross Profit Margin	40.12%	49.22%	-13.02%
Selling, General & Admin	$5.674M	$5.585M	$3.581M
YoY Change	31.56%	55.96%	129.55%
% of Gross Profit	125.06%	83.5%
Research & Development	$3.740M	$3.369M	$4.364M
YoY Change	-52.27%	-22.8%	18.72%
% of Gross Profit	82.43%	50.37%
Depreciation & Amortization	$400.0K	$200.0K	$100.0K
YoY Change	100.0%	100.0%	-23.08%
% of Gross Profit	8.82%	2.99%
Operating Expenses	$9.414M	$8.954M	$7.945M
YoY Change	-22.51%	12.7%	51.74%
Operating Profit	-$4.877M	-$2.265M	-$8.522M
YoY Change	-39.2%	-73.42%	62.82%
Interest Expense	$2.000K	$2.000K	$2.000K
YoY Change	100.0%	0.0%	-33.33%
% of Operating Profit
Other Income/Expense, Net	$461.0K	$113.0K	$3.884M
YoY Change	-58.28%	-97.09%	1025.8%
Pretax Income	-$4.420M	-$2.150M	-$4.640M
YoY Change	-36.13%	-53.66%	-5.11%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.416M	-$2.152M	-$4.638M
YoY Change	-36.16%	-53.6%	-5.13%
Net Earnings / Revenue	-39.05%	-15.84%	-104.65%
Basic Earnings Per Share
Diluted Earnings Per Share	-$185.8K	-$90.37K	-$711.7K
COMMON SHARES
Basic Shares Outstanding	23.79M shares	23.79M shares	6.497M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.70M	$20.20M	$7.300M
YoY Change	-50.27%	176.71%	62.22%
Cash & Equivalents	$18.70M	$20.20M	$7.300M
Short-Term Investments
Other Short-Term Assets	$514.0K	$2.270M	$610.0K
YoY Change	-65.73%	272.13%	158.47%
Inventory	$1.639M	$2.078M	$1.922M
Prepaid Expenses
Receivables	$7.639M	$8.980M	$4.317M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.52M	$33.55M	$14.11M
YoY Change	-36.21%	137.71%	198.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.315M	$4.616M	$2.387M
YoY Change	79.79%	93.38%	150.47%
Goodwill
YoY Change
Intangibles	$2.987M	$3.057M	$3.337M
YoY Change		-8.39%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.302M	$7.673M	$5.724M
YoY Change	28.11%	34.05%	500.63%
TOTAL ASSETS
Total Short-Term Assets	$28.52M	$33.55M	$14.11M
Total Long-Term Assets	$7.302M	$7.673M	$5.724M
Total Assets	$35.82M	$41.22M	$19.84M
YoY Change	-28.93%	107.8%	249.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.995M	$6.120M	$2.909M
YoY Change	99.8%	110.38%	-11.85%
Accrued Expenses	$85.00K	$140.0K	$2.505M
YoY Change	-97.26%	-94.41%	401.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.500M
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.261M	$10.82M	$17.05M
YoY Change	-25.91%	-36.56%	343.81%
LONG-TERM LIABILITIES
Long-Term Debt	$81.00K	$91.00K	$0.00
YoY Change	-19.0%
Other Long-Term Liabilities	$66.00K	$66.00K
YoY Change
Total Long-Term Liabilities	$147.0K	$157.0K	$0.00
YoY Change	47.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.261M	$10.82M	$17.05M
Total Long-Term Liabilities	$147.0K	$157.0K	$0.00
Total Liabilities	$9.408M	$10.98M	$17.10M
YoY Change	-25.33%	-35.82%	345.08%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$307.2M	$306.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.41M	$30.24M	$2.785M
YoY Change
Total Liabilities & Shareholders Equity	$35.82M	$41.22M	$19.84M
YoY Change	-28.93%	107.8%	249.04%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$4.416M	-$2.152M	-$4.638M
YoY Change	-36.16%	-53.6%	-5.13%
Depreciation, Depletion And Amortization	$400.0K	$200.0K	$100.0K
YoY Change	100.0%	100.0%	-23.08%
Cash From Operating Activities	-$720.0K	-$4.480M	-$6.070M
YoY Change	-91.46%	-26.19%	29.15%
INVESTING ACTIVITIES
Capital Expenditures	-$770.0K	-$1.210M	-$10.00K
YoY Change	1000.0%	12000.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.050M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$780.0K	-$1.200M	$1.040M
YoY Change	-69.65%	-215.38%	-5300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	0.000	3.460M
YoY Change	-100.02%	-100.0%	-34700.0%
NET CHANGE
Cash From Operating Activities	-720.0K	-4.480M	-6.070M
Cash From Investing Activities	-780.0K	-1.200M	1.040M
Cash From Financing Activities	-10.00K	0.000	3.460M
Net Change In Cash	-1.510M	-5.680M	-1.570M
YoY Change	-104.98%	261.78%	-66.81%
FREE CASH FLOW
Cash From Operating Activities	-$720.0K	-$4.480M	-$6.070M
Capital Expenditures	-$770.0K	-$1.210M	-$10.00K
Free Cash Flow	$50.00K	-$3.270M	-$6.060M
YoY Change	-100.6%	-46.04%	29.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	astm	Amortizationof Intangible Assets Minimum Materiality Thresholdfor Amortization Expense AmortizationofIntangibleAssetsMinimumMaterialityThresholdforAmortizationExpense	100000	USD
	astm	Amortizationof Intangible Assets Minimum Materiality Thresholdfor Amortization Expense AmortizationofIntangibleAssetsMinimumMaterialityThresholdforAmortizationExpense	100000	USD
CY2015Q2	astm	Common Stock Remaining Capacity CommonStockRemainingCapacity	7800000	USD
	astm	Convertible Preferred Stock Conversion Period ConvertiblePreferredStockConversionPeriod	P5Y
	astm	Foreign Currency Translation Gain ForeignCurrencyTranslationGain	0	USD
	astm	Foreign Currency Translation Gain ForeignCurrencyTranslationGain	10000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due OperatingAndCapitalLeasesFutureMinimumPaymentsDue	7834000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due Current OperatingAndCapitalLeasesFutureMinimumPaymentsDueCurrent	2055000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due In Four Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInFourYears	292000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due In Three Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInThreeYears	1400000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due In Two Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInTwoYears	4087000	USD
CY2015Q2	astm	Operating And Capital Leases Future Minimum Payments Due Thereafter OperatingAndCapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23787870	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4714000	USD
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3258000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5824000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6120000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8191000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8980000	USD
CY2014Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2044000	USD
CY2015Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1133000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	605000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4397000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4858000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	91000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4300000	shares
CY2014Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	348000	USD
CY2015Q2	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	317000	USD
CY2014Q4	us-gaap	Assets Assets	47579000	USD
CY2015Q2	us-gaap	Assets Assets	41219000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	41490000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	33546000	USD
CY2014Q2	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	3634000	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	3634000	USD
CY2015Q2	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	3400000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	700000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	140000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	32000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	43000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	43000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	22000	USD
CY2013Q4	us-gaap	Cash Cash	8059000	USD
CY2014Q2	us-gaap	Cash Cash	7263000	USD
CY2014Q4	us-gaap	Cash Cash	30343000	USD
CY2015Q2	us-gaap	Cash Cash	20218000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23787000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23787000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23787000	shares
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2770000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-412000	USD
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23787000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	305008000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	306625000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4633000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10628000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2152000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7014000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5009000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5009000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6901000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12469000	USD
CY2014Q2	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	200000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	246000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	672000	USD
CY2014Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	307685000	USD
CY2015Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	314699000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.18
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1281000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1432000	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-248000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1104000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-112000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	205000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1797000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	140000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	280000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	280000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	280000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	280000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3057000	USD
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	10000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	35000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	-577000	USD
	us-gaap	Gross Profit GrossProfit	-577000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	6689000	USD
	us-gaap	Gross Profit GrossProfit	11970000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-8000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4256000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	789000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3197000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2941000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1458000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-278000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	10000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1235000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3057000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	3000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	4000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	384000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	182000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1920000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	2078000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1078000	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1665000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	458000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	231000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	11938000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	10975000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47579000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41219000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11829000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10818000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	109000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-796000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-10125000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8911000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-14000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1036000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1520000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10743000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8591000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-4638000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10633000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2152000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7014000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6112000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13525000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3806000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10258000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3884000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2533000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-177000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	7945000	USD
	us-gaap	Operating Expenses OperatingExpenses	12589000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	8954000	USD
	us-gaap	Operating Expenses OperatingExpenses	18807000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8522000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13166000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2265000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6837000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7694000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	260000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1357000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4044000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2033000	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2500000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	436000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	236000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1036000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2270000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	210000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	154000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-35000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-1050000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1555000	USD
CY2014Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1474000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2892000	USD
CY2015Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1654000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3244000	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2015Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	8917000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7289000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9474000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2892000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4616000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	6000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	17000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2500000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4364000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7635000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3369000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7746000	USD
CY2014Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate	80	position
CY2014Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.30
CY2014	us-gaap	Restructuring Charges RestructuringCharges	3000000	USD
CY2015Q2	us-gaap	Restructuring Charges RestructuringCharges	3000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3000000	USD
CY2015Q2	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4432000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4432000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13590000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24439000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	4432000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	4432000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	13590000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	24439000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3581000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4954000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5585000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11061000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	451000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1614000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	149000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	35641000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	30244000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1081000	USD
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1286000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6518000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6195000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23786000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23786000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period.  The </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 25, 2015 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Vericel and its wholly-owned subsidiaries, Marrow Donation, LLC, located in San Diego, California, and Vericel Denmark ApS, in Kastrup, Demark (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  Aastrom Biosciences GmbH ceased operations in 2014.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation a Michigan corporation, which was formerly known as Aastrom Biosciences, Inc. (the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French société anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI™, and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products as well as developmental stage product candidates and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company’s products, and the successful integration and profitability of the CTRM Business.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-006531-index-headers.html	Edgar Link	pending
0001628280-15-006531-index.html	Edgar Link	pending
0001628280-15-006531.txt	Edgar Link	pending
0001628280-15-006531-xbrl.zip	Edgar Link	pending
astm-20150630.xml	Edgar Link	completed
astm-20150630.xsd	Edgar Link	pending
astm-20150630_cal.xml	Edgar Link	unprocessable
astm-20150630_def.xml	Edgar Link	unprocessable
astm-20150630_lab.xml	Edgar Link	unprocessable
astm-20150630_pre.xml	Edgar Link	unprocessable
ex311q22015.htm	Edgar Link	pending
ex312q22015.htm	Edgar Link	pending
ex321q22015.htm	Edgar Link	pending
ex322q22015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel6301510q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2015 Q3 Form 10-Q Financial Statement

#000162828015006531 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2015 Q3 Form 10-Q Financial Statement

#000162828015006531 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel